Importantly, antibody-drug conjugate (ADC) therapies designed to target HER2 or HER3 significantly diminish prostate cancer cell growth in vitro and tumor size in vivo, despite ASPN in the TME. This evidence concerns the gene ERBB3 and prostate carcinoma.